| 1 |
Lowy FD. Staphylococcus aureus infections[J]. New Engl J Med,1998, 339:520-532.
|
| 2 |
Camargo IL, Gilmore MS. Staphylococcus aureus-probing for host weakness?[J] J Bacteriol, 2008, 190:2253-2256.
|
| 3 |
Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillinresistant Staphylococcus aureus infections in the United States[J].JAMA，2007, 298:1763-1771.
|
| 4 |
Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin[J]. Lancet, 1997, 350:1670-1673.
|
| 5 |
Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility[J]. J Antimicrob Chemoth, 1997, 40:135-136.
|
| 6 |
Bae IG, Federspiel JJ, Miro JM, et al. Heterogeneous vancomycinintermediate susceptibility phenotype in bloodstream methicillinresistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance[J]. J Infect Dis, 2009, 200:1355-1366.
|
| 7 |
Fink SL, Martinello RA, Campbell SM, et al. Low prevalence of heterogeneous vancomycin- intermediate Staphylococcus aureus isolates among Connecticut veterans[J]. Antimicrob Agents Chemoth,2012, 56:582-583.
|
| 8 |
Sun W, Chen H, Liu Y, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus Isolates from 14 Cities in China[J]. Antimicrob Agents Chemoth,2009, 53:3642-3649.
|
| 9 |
Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus[J]. Clin Infect Dis, 2004, 38:448-451.
|
| 10 |
Sancak B, Ercis S, Menemenlioglu D, et al. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital[J]. J Antimicrob Chemoth, 2005,56:519-523.
|
| 11 |
Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)[J]. J Clin Microbiol, 2008,46:2950-2954.
|
| 12 |
Garnier F, Chainier D, Walsh T, et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital[J]. J Antimicrob Chemoth, 2006,57:146-149.
|
| 13 |
Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods[J]. Antimicrob Agents Chemoth, 2003,47:3040-3045.
|
| 14 |
Maor Y, Rahav G, Belausov N, et al. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center[J]. J Clin microbiol, 2007, 45:1511-1514.
|
| 15 |
Kim MN, Hwang SH, Pyo YJ, et al. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea[J]. J Clin Microbiol, 2002,40:1376-1380.
|
| 16 |
Adam HJ, Louie L, Watt C, et al. Detection and characterization of heterogeneous vancomycin- intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006[J]. Antimicrob Agents Chemoth,2010, 54:945-949.
|
| 17 |
Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital[J]. J Antimicrob chemoth,2001,47:399-403.
|
| 18 |
Leonard SN, Rossi KL, Newton KL, et al. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides[J]. J Antimicrob Chemoth, 2009,63:489-492.
|
| 19 |
Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years[J]. J Clin Microbiol, 2009,47:1640-1644.
|
| 20 |
Tenover FC, Mohammed MJ, Stelling J, et al. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing[J]. J Clin Microbiol, 2001,39:241-250.
|
| 21 |
Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin,United States, 1997-2001[J]. Clin Infect Dis, 2003,36:429-439.
|
| 22 |
Bobin-Dubreux S, Reverdy ME, Nervi C, et al. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative[J].Antimicrob Agents Chemoth, 2001,45:349-352.
|
| 23 |
Bierbaum G, Fuchs K, Lenz W, et al. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany[J]. Eur J Clin Microbiol Infect Dis, 1999,18:691-696.
|
| 24 |
Geisel R, Schmitz FJ, Thomas L, et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area[J]. J Antimicrob Chemoth, 1999,43:846-848.
|
| 25 |
Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides[J]. J Clin Microbiol, 2001,39:2439-2444.
|
| 26 |
Hubert SK, Mohammed JM, Fridkin SK, et al. Glycopeptideintermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U S hospitals[J]. J Clin Microbiol, 1999,37:3590-3593.
|
| 27 |
Reverdy ME, Jarraud S, Bobin-Dubreux S, et al. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals[J]. Clin Microbiol Infect, 2001,7:267-272.
|
| 28 |
Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand[J]. J Clin Microbiol, 2001,39:591-595.
|
| 29 |
Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus[J].Emerg Infect Dis, 2001,7:327-332.
|
| 30 |
Wootton M, MacGowan AP, Walsh TR, et al. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides[J]. J Clin microbiol, 2007,45:329-332.
|
| 31 |
Yusof A, Engelhardt A, Karlsson A, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptideintermediate Staphylococcus aureus (GISA), in particular,heterogeneous GISA[J]. J Clin Microbiol, 2008,46:3042-3047.
|
| 32 |
Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus[J]. J Clin Microbiol,2009,47:2013-2017.
|
| 33 |
Pierard D, Vandenbussche H, Verschraegen I, et al. Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in:a Belgian hospital[J]. Patholbiol, 2004,52:486-488.
|
| 34 |
Voss A, Mouton JW, van Elzakker EP, et al. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus(GISA) and heterogeneous GISA (h-GISA)[J]. Ann Clin Microbiol Antimicrob, 2007, 6:9.
|
| 35 |
Fong RK, Low J, Koh TH, et al. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA)and heteroresistant vancomycin-intermediate Staphylococcus aureus(hVISA) in a tertiary care institution in Singapore[J]. Eur J Clin Microbiol Infect Dis, 2009,28:983-987.
|
| 36 |
Maor Y, Hagin M, Belausov N, et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia[J]. J Infect Dis,2009,199:619-624.
|
| 37 |
Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin[J]. Lancet, 1999,353:1587-1588.
|
| 38 |
Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility[J]. Clin Infect Dis,2004,38:521-528.
|
| 39 |
Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus[J]. J Infect Dis, 2009,199:605-609.
|
| 40 |
Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinsusceptible MRSA[J]. Antimicrob Agents Chemoth, 2009,53:3447-3452.
|
| 41 |
Lalani T, Federspiel JJ, Boucher HW, et al. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients[J]. J Clin Microbiol, 2008,46:2890-2896.
|
| 42 |
Szabó J. hVISA/VISA: diagnostic and therapeutic problems[J]. Expert Rev Anti-Infect Ther, 2009,7:1-3.
|
| 43 |
Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know[J]. Clin Infect Dis, 2001,32:108-115.
|
| 44 |
Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin[J]. Antimicrob Agents Chemoth, 1999,43:1747-1753.
|
| 45 |
Jevitt LA, Smith AJ, Williams PP, et al. In vitro activities of Daptomycin,Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including Vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium[J]. Microb Drug Resist, 2003,9:389-393.
|
| 46 |
Kola A, Kirschner P, Gohrbandt B, et al. An infection with linezolidresistant Staphylococcus aureus in a patient with left ventricular assist system[J]. Scandinav J Infect Dis, 2007,39:463-465.
|
| 47 |
Tillotson GS, Draghi DC, Sahm DF, et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study[J]. J Antimicrob Chemoth, 2008,62:109-115.
|
| 48 |
Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus[J]. Lancet, 2001,358:207-208.
|
| 49 |
Huang YT, Hsiao CH, Liao CH, et al. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycinintermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan[J]. J Clin Microbiol, 2008,46:1132-1136.
|
| 50 |
Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus[J]. J Antimicrob Chemoth, 2006,58:338-343.
|
| 51 |
Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptideintermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates[J]. Antimicrob Agents Chemoth, 2006,50:4195-4197.
|
| 52 |
Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations[J]. J Antimicrob Chemoth, 2009, 63:155-160.
|
| 53 |
Huang YT, Liao CH , Teng LJ, et al. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan[J]. Clin Microbiol Infect, 2008,14:124-129.
|